<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35714273</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial.</ArticleTitle><Pagination><StartPage>2063630</StartPage><MedlinePgn>2063630</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2063630</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2022.2063630</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To evaluate the immunogenicity, safety and lot-to-lot consistency of an inactivated enterovirus 71 (EV71) vaccine cultured in bioreactors with different specifications after full immunization.</AbstractText><AbstractText Label="METHODS">A randomized, double-blind trial was performed in 3,000 children aged 6&#x2009;~&#x2009;35&#x2009;months with six vaccine batches, which were prepared in 40&#x2009;L and 150&#x2009;L bioreactors for three consecutive batches respectively. Children were immunized on day 0 and 28, serum samples were collected on day 0 and 56, and neutralizing antibody titers were determined by the microcytopathic method. Immediate reactions were recorded within 30&#x2009;min, local and systemic symptoms were recorded within 0&#x2009;~&#x2009;28&#x2009;days, and serious adverse events were recorded within 6&#x2009;months.</AbstractText><AbstractText Label="RESULTS">After immunization with two doses of the inactivated EV71 vaccine, the neutralizing antibody GMT was 825.52&#x2009;&#xb1;&#x2009;4.09, and the positive conversion rate was 96.18%, with no significant difference. The 95% CI of the serum neutralizing antibody GMT ratio between the two groups after immunization with the three vaccine batches produced in the 150&#x2009;L and 40&#x2009;L bioreactors ranged from .67&#x2009;~&#x2009;1.5. The overall incidence of adverse reactions, mainly grade 1 reactions, for all 6 batches from 0 to 28&#x2009;days after vaccination was 49.62%, with no significant difference (p&#x2009;=&#x2009;.8736). The incidence of systemic adverse reactions, primarily fever and diarrhea, was 45.14%; the incidence of local adverse reactions, primarily erythema and tenderness, was 9.43%.</AbstractText><AbstractText Label="CONCLUSION">The EV71 vaccine was highly immunogenic and safe in children aged 6-35&#x2009;months, and 6 consecutive batches produced by the two bioreactors with different specifications were consistent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jinhua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Pengfei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center of Disease Control and Prevention, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaoqi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis virus and Enterovirus Vaccine, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Fanyue</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center of Disease Control and Prevention, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xinguo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Meizhi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Disease Prevention and Control, Pei County Center for Disease Control and Prevention, Pei County, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis virus and Enterovirus Vaccine, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Pei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Public Health, Southeast University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiujuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Disease Prevention and Control, Pei County Center for Disease Control and Prevention, Pei County, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Changfu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Tingbo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Research and Development, National Vaccine &amp; Serum Institute, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qingliang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Hongqiao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiuling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Shanghai Institute of Biological Products Co., Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Research and Development, Wuhan Institute of Biological Products Co., Ltd, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Fengcai</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1644-0006</Identifier><AffiliationInfo><Affiliation>Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center of Disease Control and Prevention, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inactivated enterovirus 71 vaccine (Vero Cell)</Keyword><Keyword MajorTopicYN="N">consistency</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList><CoiStatement>Clinical Trials identifier: CTR20191004, May 29, 2019.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>17</Day><Hour>15</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35714273</ArticleId><ArticleId IdType="pmc">PMC9897631</ArticleId><ArticleId IdType="doi">10.1080/21645515.2022.2063630</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, et al. Neurologic complications in children with enterovirus 71 infection[J]. N Engl J Med. 1999;341(13):936&#x2013;7. PMID: 10 498488. doi:10.1056/NEJM199909233411302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411302</ArticleId><ArticleId IdType="pubmed">10498488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang PC, Chen SC, Chen KT.. The current status of the disease caused by enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development. Int J Environ Res Public Health. 2016;13(9):890. PMID: 27618078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5036723</ArticleId><ArticleId IdType="pubmed">27618078</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu SL, Pan H, Liu P, Amer S, Chan T-C, Zhan J, Huo X, Liu Y, Teng Z, Wang L, et al. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China fro-m 2008 to 2014. Rev Med Virol. 2015;25(2):115&#x2013;28. PMID: 25704797.</Citation><ArticleIdList><ArticleId IdType="pubmed">25704797</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Clinical considerations for evaluation of vaccines for prequalification. Points to consider for manufacturers of human vaccines; 2010. 
[accessed 2013 Set
12]. http://www.who.int/immunization/standards/vaccine/quality/clinicalconsiderations/oct10.pdf</Citation></Reference><Reference><Citation>Chen YJ, Meng FY, Mao Q, Li J-X, Wang H, Liang Z-L, Zhang Y-T, Gao F, Chen Q-H, Hu Y, et al. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial. Hum Vaccin Immunot Her 2014;10(5):1366&#x2013;72. PMID:24633366. doi:10.4161/hv.28397.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.28397</ArticleId><ArticleId IdType="pmc">PMC4896521</ArticleId><ArticleId IdType="pubmed">24633366</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Wang Y, Bian L, Xu M, Liang Z.. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016;15(5):599&#x2013;606. PMID: 26732723. doi:10.1586/14760584.2016.1138862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1138862</ArticleId><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z-Q, Qin ZQ, Tan HF, Zhang C-H, Xu J-X, Chen J, Ni L-H, Yun X-X, Cui M, Huang Y, et al. Analysis of the coverage of inactivated enterovirus 71 (EV71) vaccine and adverse events following immunization with the EV71 vaccine among children from 2016 to 2019 in Guangzhou. Expert Rev Vaccines. 2021;20(7):907&#x2013;18. PMID: 34036862. doi:10.1080/14760584.2021.1933451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1933451</ArticleId><ArticleId IdType="pubmed">34036862</ArticleId></ArticleIdList></Reference><Reference><Citation>Li ML, Shih SR, Tolbert BS, Brewer G. Enterovirus A71 vaccines. Vaccines (Basel). 2021;9(3):199. PMID: 33673595. doi:10.3390/vaccines9030199.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9030199</ArticleId><ArticleId IdType="pmc">PMC7997495</ArticleId><ArticleId IdType="pubmed">33673595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li X-L, Mao Q-Y, Tao H, Zhang Y-T, Yao X, Chu K, Chen Q-H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381(9882):2024&#x2013;32. PMID: 23726161. doi:10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauta J. Vaccine equivalence and noninferiority immunogenicity trials. Statistics in clinical vaccine trials. Springer; 2011. doi:10.1007/978-3-642-14691-6_6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-14691-6_6</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidelines on clinical evaluation of vaccines: regulatory expectations[J]. WHO Technical Report Series, 2004. Accept from: https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9</Citation></Reference><Reference><Citation>National Medical Products Administration . Guidelines for adverse event classification standards for clinical trials of preventive vaccines. [DC]. National Medical Products Administration, December 31; 2019. Available from: http://english.nmpa.gov.cn/2019-12/31/c_448385.htm</Citation></Reference><Reference><Citation>Zhu F-C, Liang Z-L, Li XL, Ge H-M, Meng F-Y, Mao Q-Y, Zhang Y-T, Hu Y-M, Zhang Z-Y, Li J-X, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2013;381(9871):1037&#x2013;45. PMID: 23352749. doi:10.1016/S0140-6736(12)61764-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61764-4</ArticleId><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng FY, Li JX, Li XL, Chu K, Zhang Y-T, Ji H, Li L, Liang Z-L, Zhu F-C. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum Vaccin Immunother. 2012;8(5):668&#x2013;74. PMID: 22634437. doi:10.4161/hv.19521.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.19521</ArticleId><ArticleId IdType="pubmed">22634437</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W, Jin P, Li JX, Zhu FC, Liu P. Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints. Expert Rev Vaccines. 2017;16(9):945&#x2013;49. PMID: 28548626. doi:10.1080/14760584.2017.1335603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2017.1335603</ArticleId><ArticleId IdType="pubmed">28548626</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818&#x2013;28. PMID: 24571754. doi:10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829&#x2013;37. PMID: 24571755. doi:10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Tang F, Wang Z, et al. Post-Marketing safety surveillance for inactivated enterovirus 71 vaccines in Jiangsu, China from 2017 to 2019. Vaccine. 2021;39(9):1415&#x2013;19. PMID: 3354 1 795. doi:10.1016/j.vaccine.2021.01.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.01.048</ArticleId><ArticleId IdType="pubmed">33541795</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai YH, Li LI, Zhang JN, et al. Post-Marketing assessment on safety of inactived enterovirus type 71 vaccine by proactive monitoring[J]. Chin J Public Health. 2017;33(7):1045&#x2013;1047. doi:10.11847/zgggws2017-33-07-03.</Citation><ArticleIdList><ArticleId IdType="doi">10.11847/zgggws2017-33-07-03</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y-M, et al. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol. 20(12):1805&#x2013;11. PMID: 24108780. doi:10.1128/CVI.00491-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00491-13</ArticleId><ArticleId IdType="pmc">PMC3889509</ArticleId><ArticleId IdType="pubmed">24108780</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Liu L, Dong C, et al. Consistency of various batches of inactivated enterovirus 71 vaccine [J]. Chin J Biol. 2015;28(3):6.</Citation></Reference><Reference><Citation>Xu Q, et al. Interchangeability of two enterovirus 71 inactivated vaccines in Chinese children: a phase IV, open-label, and randomized controlled trial. Vaccine. 2020;38(12):2671&#x2013;77. PMID: 32067817. doi:10.1016/j.vaccine.2020.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.02.013</ArticleId><ArticleId IdType="pubmed">32067817</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu H, Shimizu Y, Takeuchi Y, Ishiko H, Takada H. Outbreak of severe neurologic involvement associated with enterovirus 71 infection. Pediatr Neurol. 1999;20(1):17&#x2013;23. PMID: 10029254. doi:10.1016/s0887-8994(98)00087-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0887-8994(98)00087-3</ArticleId><ArticleId IdType="pubmed">10029254</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum LC, Wong KT, Lam SK, Chua KB, Goh AY. Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitis. Lancet. 1998;352(9137):1391. PMID: 9802304. doi:10.1016/s0140-6736(05)60789-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(05)60789-1</ArticleId><ArticleId IdType="pubmed">9802304</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein MH. EV71 vaccines: a first step towards multivalent hand, foot and mouth disease vaccines. Expert Rev Vaccines. 2015;14(3):337&#x2013;40. PMID: 25536888.</Citation><ArticleIdList><ArticleId IdType="pubmed">25536888</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>